Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.
Phase of Trial: Phase IV
Latest Information Update: 12 Jan 2015
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 12 Jan 2015 According to a Celgene Corporation media release, submission of lenalidomide in the U.S. and discussion of lenalidomide for non-deletion 5q myelodysplastic syndrome with regulatory authorities in additional geographies is expected in 2015.
- 16 Sep 2014 New trial record